350 руб
Журнал «Вопросы биологической, медицинской и фармацевтической химии» №7 за 2011 г.
Статья в номере:
О необходимости создания отечественного противоопухолевого препарата бактериальной L-аспарагиназы (Обзор)
Ключевые слова: L-аспарагиназа L-глутаминаза острый лимфобластный лейкоз онкотерапия Helicobacter pylori Escherichia coli Erwinia carotovora
Авторы:
Ю.В. Красоткина - к.б.н., вед. науч. сотрудник, лаборатория медицинской биотехнологии, Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича РАМН (Москва) Н.Н. Соколов - д.б.н., профессор, руководитель лаборатории медицинской биотехнологии, Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича РАМН. E-mail: sokolov2144@yandex.ru
Аннотация:
Рассмотрена история открытия и изучения бактериальной L-аспарагиназы, современное представление о механизме его противоопухолевого действия. Уделено особое внимание клиническому применению аспарагиназы в качестве противолейкозного препарата, проведено сравнение преимуществ и недостатков основных современных аспарагиназ, используемых в онкотерапии. Проанализирована необходимость и возможность создания отечественного препарата аспарагиназы, удовлетворяющего потребностям российских клиник.
Страницы: 37-45
Список источников
  1. Карачунский А.И. Лечение острой лимфобластной лейкемии у детей: российские достижения // Человек и лекарство. 2008. Т. 1. № 32. Р. 6-7.
  2. Aghaiypour K., Wlodawer A., Lubkowski J. Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-Asparaginase // Biochemistry. 2001. V. 40. P. 5655-5664.
  3. Andrulis I.L., Argonza R., Cairney A.E. Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin // Somat. Cell Mol. Genet. 1990. V. 16. P. 59-65.
  4. Apostolidou E., Swords R., Alvarado Y., Giles F.J. Treatment of acute lymphoblastic leukaemia: a new era // Drugs. 2007. V. 67. P. 2153-2171.
  5. Aslanian A.M., Fletcher B.S., Kilberg M.S. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells // Biochem. J. 2001. V. 357. P. 321-328.
  6. Chang J.E., Medlin S.C., Kahl B.S., Longo W.L., Williams E.C., Lionberger J., Kim K., Kim J., Esterberg E., Juckett M.B. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia // Leuk. Lymphoma. 2008. V. 49. № 12. P. 2298-2307.
  7. Ciudad J., San Miguel J.F., López-Berges M.C., Vidriales B., Valverde B., Ocqueteau M., Mateos G., Caballero M.D., Hernandez J., Moro M.J., Mateos M.V., Orfao A. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia // J. Clin. Oncol. 1998. V. 16. № 12. P. 3774-3781.
  8. Clementi A. La desamidation enzymatique de l'asparagine chez les differentes especes animals et la signification physiologique de sa presence dans l'organisme // Arch. Intern. Physiol. 1992. V. 19. P. 369.
  9. Derst C., Henseling J., Rohm K.H. Engineering the substrate specificity of Escherichia coli asparaginase II. Selective reduction of glutaminase activity by amino acid replacements at position 248 // Protein Science. 2000. V. 9. № 10. P. 2009-2017.
  10. Dhavala P., Krasotkina J., Dubreuil C., Papageorgiou A.C. Expression, purification and crystallization of Helicobacter pylori L-asparaginase // Acta Crystallogr. Sect. F. 2008. V. 1. № 64. P. 740-742.
  11. Dinndorf P.A., Gootenberg J., Cohen M.H., Keegan P., Pazdur R. Treatment of Children with Acute Lymphoblastic Leukemia (ALL) FDA Drug Approval Summary: Pegaspargase (Oncaspar) for the First-Line // Oncologist. 2007. V. 12. P. 991-998.
  12. Distasio J.A., Niederman R.A., Kafkewitz D., Goodman D. Purification and characterization of L-asparaginase with anti-lymphoma activity from Vibrio succinogenes // J. Biol. Chem. 1976. V. 251. P. 6929-6933.
  13. Distasio J.A., Salazar A.M., Nadsji M., Durden D.L. Glutaminase-free asparaginase from Vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity // Int. J. Cancer. 1982. V. 30. P. 343-347.
  14. Duval M., Suciu S., Ferster A., Rialland X., Nelken B., Lutz P., Benoit Y., Robert A., Manel A.M., Vilmer E., Otten J., Philippe N. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial // Blood. 2002. V. 99. P. 2734-2739.
  15. Pat. № PCT/US98/11905 (США). Utilization of Wollinela succinogenes asparaginase to treat diseases associated with asparaginase dependence / D. Durden.
  16. Durden D.L. and Distasio J.A. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes // Cancer Res. 1980. V. 40. P. 1125-1229.
  17. Dox A.W. The intracellular enzymes of lower fungi, especially those of Penicillium camemberti // J. Biol. Chem. 1909. V. 6. P. 461 - 467.
  18. Fine B.M., Kaspers G.J., Ho M Loonen A.H., Boxer L.M. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia // Fine. Cancer. Res. 2005. V. 65. № 1. P. 291-299.
  19. Felix C.A., Lange B.J., Chessells J.M. Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000 // Hematology. 2000. P. 285-302.
  20. Fu C.H., Sakamoto K.M. PEG-asparaginase // Expert Opin. Pharmacother. 2007. V. 12. P. 19771984.
  21. Furth O., Friedmann M. Uber die Verbreitung asparaginspaltender Organfermente // Biochem. Z. 1910. V. 26. P. 435-440.
  22. Gladilina Yu.A., Sokolov N.N., Krasotkina J.V. Cloning, expression and purification of Helicobacter pylori L-Asparaginase // Biochemistry (Moscow). 2009. V. 3. № 1. P. 89-91.
  23. Greenstein J.P., and Price V.E. a-Keto acid-activated glutaminase and asparaginase // J. Biol. Chem. 1949. V. 178. P. 695 - 705.
  24. van Grotel M., Meijerink J.P., Beverloo H.B., Langerak A.W., Buys-Gladdines J.G., Schneider P., Poulsen T.S., den Boer M.L., Horstmann M., Kamps W.A., Veerman A.J., van Wering E.R., van Noesel M.M., Pieters R. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols // Haematologica. 2006. V. 91. № 9. Р. 1212-1221.
  25. Grover C.E., Chibnall A.C. The enzymic deamidation of asparagine in the higher plants // Biochem. J. 1927. V. 21. P. 857-868.
  26. Horowitz B., Madras B.K., Meister A., Old L.J., Boyes E.A., Stockert E. Asparagine synthetase activity of mouse leukemias // Science. 1968. V. 160. P. 533535.
  27. Hutson R.G., Kitoh T., Moraga Amador D.A., Cosic S., Schuster S.M., Kilberg M.S. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells // Am. J. Physiol. 1997. V. 272. P. 1691-1699.
  28. Iwamoto S., Mihara K., Downing J.R., Pui C-H., Campana D. Mesenchymal cells regulate the response of acute lymphoblastiс leukemia cells to asparaginase // J. Clin. Invest. 2007. V. 117. P. 1049-1057.
  29. Irino T., Kitoh T., Koami K., Kashima T., Mukai K., Takeuchi E., Hongo T., Nakahata T., Schuster S.M., Osaka M. Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression // J. Mol. Diagn. 2004. V. 6. P. 217-224.
  30. Kafkewitz D., Bendich A. Enzyme-induced asparagine and glutamine depletion and immune system function // Am. J. Clin. Nutr. 1983. V. 37. P. 1025-1030.
  31. Kidd J. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum or rabbit serum // J. Exp. Med. 1953. V. 98. P. 565-581.
  32. Killander D., Dohlwitz A., Engstedt L., et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia // Cancer. V. 37. № 1. Р. 220-228.
  33. Krebs H.A. Manometric determination of L-aspartic acid and L-asparagine // Biochem. J. 1950. V. 47. P. 605-612.
  34. Lang S. Uber desamidierung im Tierkorper // Beitr chem. physiol. pathol. 1904. V. 5. P. 321-345.
  35. Lazarus H., McCoy T.A., Farber S., Barell E.F., Foley G.E. Nutritional requirements of human leukemic cells. Asparagine requirements and the effect of Lasparaginase // Exp. cell res. 1969. V. 57. P. 134 - 138.
  36. Mashburn L.T., Wriston J.C. Change in ribonuclease concentrations in L-asparaginase treated lymphosarcomata // Nature. 1966. V. 211. P. 1403-1404.
  37. Mashburn L., Wriston J.C. Tumor inhibitory effects of L-asparaginase from Escherchia coli // Arch. Biochem. Biophys. 1964. V. 105. P. 450-452.
  38. Reinert R.B., Oberle L.M., Wek S.A., Bunpo P., Wang X.P., Mileva I., Goodwin L.O., Aldrich C.J., Durden D.L., McNurlan M.A., Wek R.C., and Anthony T.A. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase // J. Biol. Chem. 2006. V. 281. P. 31222-31233.
  39. Roberts J., Prager M., Bachynsky N. The antitumor activity of Escherichia coli L-asparaginase // Cancer Res. 1966. V. 26. P. 2213-2217.
  40. Rumiantsev A.G., Samochatova E.V., Karachunsky A.I., et al. Intensive chemotherapy for acute leukemias (AL) in childhood with BFM protocols. Moscow experiences 1990-92. First successes and failures // Haematol. Blood Transfus. 1994. V. 36. P. 344-346.
  41. Sansom B.F., Barry J.M. The use of asparagine and glutamine for the biosynthesis of casein and plasma proteins // Biochem. J. 1958. V. 68. P. 487-493.
  42. А. von Stackelberg A., Karatchunsky J., Kudrjashova N., Miakova L., Belikova A., Rumiantzev R., Hartmann and G. Henze. Toxicity, supportive sare and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90 and MB 91 // Eur. J. Cancer. 1999. V. 9. № 35. P. 1349-1355.
  43. Stams W.A., den Boer M.L., Beverloo H.B., van Wering E.R. and Pieters R. Upregulation of asparagine synthetase and cell cycle arrest in t(12;21)-positive ALL // Leukemia. 2005. V. 19. P. 318-319.
  44. Stams W.A., den Boer M.L., Beverloo H.B., Meijerink J.P., Stigter R.L., van Wering E.R., Janka-Schaub G.E., Slater R., Pieters R. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL // Blood. 2003. V. 101. № 7. Р. 2743-2747.
  45. Story M.D., Voehringer D.W., Stephens L.C., Meyn R.E. L-asparaginase kills lymphoma cells by apoptosis // Cancer Chemother. Pharmacol. 1993. V. 32. P. 129-133.
  46. Ueno T., Ohtawa K., Mitsui K., Kodera Y., Hiroto M., Matsushima A., Inada Y., Nishimura H. Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase // Leukemia. 1997. V. 11. P. 1858-1861.
  47. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions // Biomaterials. 2001. V. 22. P. 405-417.
  48. Waber D.P., Shapiro B.L., Carpentieri S.C., Gelber R.D., Zou G., Dufresne A., Romero I., Tarbell N.J., Silverman L.B., Sallan S.E. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01 // Cancer. 2001. V. 92. № 1. P. 15-22.
  49. Wacker P., Land V.J., Camitta B.M., Kurtzberg J., Pullen J., Harris M.B., Shuster J.J. Children's Oncology Study Group. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study // J. Pediatr. Hematol. Oncol. 2007. 29. № 9. Р. 627-632.
  50. Warrell R.P. Jr., Arlin Z.A., Gee T.S., Chou T.C., Roberts J., Young C.W. Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia // Cancer Treat. Rep. 1982. V. 66. № 7. Р. 1479-1485.
  51. Williams D.A. A new mechanism of leukemia drug resistance // N. Engl. J. Med. 2007. V. 357. № 1. Р. 77-78.
  52. Zage P.E., Kletzel M., Murray K., Marcus R., Castleberry R., Zhang Y., London W.B., Kretschmar C. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group // Pediatr. Blood Cancer. 2008. V. 51. № 6. Р. 747-753.